JAK Inhibitor Before Donor Stem Cell Transplant in Treating Patients With Primary or Secondary Myelofibrosis
Status:
Recruiting
Trial end date:
2026-06-11
Target enrollment:
Participant gender:
Summary
This phase II trial studies how well giving a JAK inhibitor before a donor stem cell
transplant works in treating patients with myelofibrosis that developed without another
condition (primary) or evolved from other bone marrow disorders (secondary). JAK inhibitors
are a class of drugs that may stop the growth of abnormal cells by blocking an enzyme needed
for cell growth. Giving a JAK inhibitor such as ruxolitinib before a donor stem cell
transplant may help reduce symptoms of myelofibrosis such as inflammation and enlargement of
the spleen, improve the patient's general physical condition, and prevent complications from
occurring after the transplant. Infusing healthy stem cells from a donor into the patient may
help the patient's bone marrow work normally and make stem cells, red blood cells, white
blood cells, and platelets. Giving a JAK inhibitor before a donor stem cell transplant may
help improve transplant outcomes in patients with myelofibrosis.
Phase:
Phase 2
Details
Lead Sponsor:
Fred Hutchinson Cancer Research Center
Collaborators:
Incyte Corporation National Cancer Institute (NCI) National Heart, Lung, and Blood Institute (NHLBI)